Protagonist Therapeutics, Inc. discovers and develops peptide-based therapeutic drugs. It is developing rusfertide (PTG-300), an injectable hepcidin mimetic that is in Phase II clinical trials for the treatment of patients with polycythemia vera and hereditary hemochromatosis. PN-943, an oral, alpha-4-beta-7 integrin-specific antagonist peptide, is in clinical trials.
Market Cap | 1.171 Billion | Shares Outstanding | 57.53 Million | Avg 30-day Volume | 583.862 Thousand |
P/E Ratio | 0.0 | Dividend Yield | 0.0 | EPS | -0.64 |
Price to Revenue | 0.0 | Debt to Equity | 0.0 | EBITDA | -154.206 Million |
Price to Book Value | 3.2672 | Operating Margin | 0.0 | Enterprise Value | 664.435 Million |
Current Ratio | 11.658 | EPS Growth | 0.026 | Quick Ratio | 11.51 |
1 Yr BETA | 0.519 | 52-week High/Low | 30.1 / 7.45 | Profit Margin | 0.0 |
Operating Cash Flow Growth | -14.878 | Free Cash Flow to Firm (FCFF) TTM | -110.486 Million | Free Cash Flow to Equity (FCFE) TTM | |
Altman Z-Score | 18.0728 |
Please sign in first
none
none
26 Thousand total shares from 2 transactions
Insider Name | Type | Last Reported Shares Held | Last Reported Date | Filings in past year |
---|---|---|---|---|
|
0 | 2023-10-26 | 2 | |
GUPTA SUNEEL CHIEF DEVELOPMENT OFFICER |
|
168,317 | 2023-10-19 | 3 |
PATEL DINESH V PH D PRESIDENT AND CEO |
|
609,347 | 2023-10-18 | 3 |
ALI ASIF CHIEF FINANCIAL OFFICER |
|
31,036 | 2023-05-31 | 3 |
|
21,506 | 2023-04-10 | 2 | |
MOLINA ARTURO MD CHIEF MEDICAL OFFICER |
|
43,125 | 2023-01-16 | 1 |
|
30,000 | 2023-01-16 | 1 | |
|
30,000 | 2023-01-16 | 1 | |
|
30,000 | 2023-01-16 | 1 | |
|
30,000 | 2023-01-16 | 1 | |
|
30,000 | 2023-01-16 | 1 | |
LIU DAVID Y CHIEF R&D STRATEGY OFFICER |
|
167,590 | 2022-11-16 | 0 |
KALKOFEN DONALD A. CHIEF FINANCIAL OFFICER |
|
63,521 | 2022-02-15 | 0 |
SAKS SAMUEL R CHIEF MEDICAL OFFICER |
|
104,000 | 2021-02-26 | 0 |
|
0 | 2020-08-11 | 0 | |
SHAMES RICHARD S. CHIEF MEDICAL OFFICER |
|
32,021 | 2019-02-28 | 0 |
MURPHY NIALL VP, CONTROLLER, INTERIM PAO |
|
0 | 2019-01-11 | 0 |
O'NEIL THOMAS P. CHIEF FINANCIAL OFFICER |
|
30,560 | 2018-08-15 | 0 |
|
0 | 2018-05-29 | 0 | |
|
No longer subject to file | 2018-05-17 | 0 | |
ADAGE CAPITAL PARTNERS GP, L.L.C. |
|
No longer subject to file | 2017-12-31 | 0 |
|
0 | 2017-05-25 | 0 | |
HODDER WILLIAM A SR. VP - CORPORATE DEVELOPMENT |
|
0 | 2016-10-11 | 0 |
|
2,449,183 | 2016-08-16 | 0 | |
|
2,099,482 | 2016-08-16 | 0 |
Reporting Owners | Filing Date | Trans Date | Trans Code | Shares | Share Price | Acquired Disposed |
Shares Owned after | D/I | 10b5 | Perf 1d* | Perf 5d* | Perf 1m* | Max Gain | Max Gain Days | Max Loss | Max Loss Days |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
2023-10-30 16:31:33 -0400 | 2023-10-26 | A | 45,000 | a | 45,000 | direct | ||||||||||
2023-10-23 16:31:12 -0400 | 2023-10-19 | M | 20,000 | $7.38 | a | 168,317 | direct | -1.1228 | 2.0351 | 47.0175 | 47.0175 | 31 | -1.193 | 4 | ||
2023-10-23 16:31:12 -0400 | 2023-10-19 | M | 20,000 | d | 50,000 | direct | ||||||||||
2023-10-19 16:55:30 -0400 | 2023-10-18 | M | 6,000 | $4.21 | a | 609,347 | direct | -2.5659 | -2.3578 | 26.491 | 28.7101 | 30 | -2.5659 | 2 | ||
2023-10-19 16:55:30 -0400 | 2023-10-18 | M | 6,000 | d | 54,000 | direct |
* -
Code | Definition |
---|---|
A | Grant, award or other acquisition pursuant to Rule 16b-3(d) |
C | Conversion of derivative security |
D | Disposition to the issuer of issuer equity securities pursuant to Rule 16b-3(e) |
E | Expiration of short derivative position |
F | Payment of exercise price or tax liability by delivering or withholding securities incident to the receipt, exercise or vesting of a security issued in accordance with Rule 16b-3 |
G | Bona fide gift |
H | Expiration (or cancellation) of long derivative position with value received |
I | Discretionary transaction in accordance with Rule 16b-3(f) resulting in acquisition or disposition of issuer securities |
J | Other acquisition or disposition |
L | Small acquisition under Rule 16a-6 |
M | Exercise or conversion of derivative security exempted pursuant to Rule 16b-3 |
O | Exercise of out-of-the-money derivative security |
P | Open market or private purchase of non-derivative or derivative security |
S | Open market or private sale of non-derivative or derivative security |
U | Disposition pursuant to a tender of shares in a change of control transaction |
W | Acquisition or disposition by will or the laws of descent and distribution |
X | Exercise of in-the-money or at-the-money derivative security |
Z | Deposit into or withdrawal from voting trust |
Updated throughout the day, this shows the number of shares available to borrow. Data provided by Interactive Brokers
Security | Date/Time | Rebate Rate | Fee Rate | Shares Available |
---|---|---|---|---|
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 22:15:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 21:45:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 21:15:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 20:45:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 20:15:07 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 19:45:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 19:15:03 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 18:45:03 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 18:15:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 17:45:03 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 17:15:03 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 16:45:05 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 16:15:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 15:45:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 15:15:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 14:45:04 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 14:15:03 UTC | 4.79 | 0.53 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 13:45:03 UTC | 4.6073 | 0.7127 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 13:15:04 UTC | 4.6073 | 0.7127 | 950000 |
PROTAGONIST THERAPEUTICS INC PTGX | 2023-12-08 12:45:05 UTC | 4.6073 | 0.7127 | 950000 |
Holder | Issuer | Net Short Position | Position Date | Origin |
---|---|---|---|---|
AQR Funds- AQR Small Cap Relaxed Constraint Equity Fund | PTGX | -90.0 shares, $-1080.9 | 2019-09-30 | N-PORT |
Advanced Series Trust- AST QMA U.S. Equity Alpha Portfolio | PTGX | -3700.0 shares, $-65564.0 | 2021-09-30 | N-PORT |